Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
23.27
+0.16 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2023
January 26, 2023
Via
Benzinga
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
January 24, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis' Patent Decision In Line With Expectations, But Analysts Say Stock Overhang Could Continue
January 20, 2023
Via
Benzinga
6 Analysts Have This to Say About Exelixis
January 11, 2023
Via
Benzinga
Is Exelixis Stock a Buy Now?
December 29, 2022
Don't be too quick to dismiss this company as a one-trick pony.
Via
The Motley Fool
What 5 Analyst Ratings Have To Say About Exelixis
December 09, 2022
Via
Benzinga
Where Exelixis Stands With Analysts
December 09, 2022
Via
Benzinga
Exelixis Announces Update on Patent Litigation with MSN Laboratories
January 19, 2023
From
Exelixis, Inc.
Via
Business Wire
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
January 08, 2023
From
Exelixis, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Exelixis
November 02, 2022
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Exposures
COVID-19
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 — Presentation to be webcast on www.exelixis.com —
January 03, 2023
From
Exelixis, Inc.
Via
Business Wire
2 Top Biotech Stocks to Buy for the Long Haul
December 25, 2022
These mid-cap biotechs are solid long-term choices.
Via
The Motley Fool
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
December 22, 2022
From
Exelixis, Inc.
Via
Business Wire
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
December 21, 2022
These could become hot buys once investors pivot back to growth stocks.
Via
The Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
December 16, 2022
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
Via
The Motley Fool
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
December 10, 2022
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.
Via
The Motley Fool
Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting
December 09, 2022
Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study
Via
Benzinga
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
3 Stocks to Buy Hand Over Fist in December
December 03, 2022
These stocks could be big winners.
Via
The Motley Fool
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
November 30, 2022
From
Exelixis, Inc.
Via
Business Wire
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
November 30, 2022
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.
Via
The Motley Fool
The Smartest Stocks to Buy With $20 Right Now
November 16, 2022
You don't need a mountain of cash to begin building wealth on Wall Street.
Via
The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less than $20
November 12, 2022
These stocks are still bargain-priced but benefit from long-term trends.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Here's Why This Growth Stock Is Already My 2022 Winner
November 09, 2022
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Via
The Motley Fool
Looking Into Exelixis's Return On Invested Capital
November 08, 2022
Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters.
Via
Benzinga
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
November 03, 2022
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.